Literature DB >> 25719455

Mass spectrometry in leukemia research and treatment.

John Roboz1, Gail J Roboz.   

Abstract

Mass spectrometry (MS) is a complex analytical chemistry tool that allows qualitative and quantitative assessments of the components of complex chemical compounds. Applications of MS in medicine include the identification and quantification of drugs and metabolites; identification of proteins, biopolymers and disease markers and investigation of differential protein expression and proteins altered by mutations and/or post-translational changes. A variety of MS methods and technologies now play valuable and expanding roles in the diagnosis and monitoring of acute leukemia, as well as in identification of therapeutic targets and biomarkers, drug discovery, and other important areas of leukemia research. The objective of this review is to present a clinically oriented review of the roles of MS in the research, diagnosis and therapy of acute leukemia.

Entities:  

Keywords:  MALDI-TOF; acute myeloid leukemia; genotyping; mass spectrometry; myelodysplastic syndrome; proteomics; quantification techniques; tyrosine kinase inhibitors

Mesh:

Year:  2015        PMID: 25719455     DOI: 10.1586/17474086.2015.1018889

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  4 in total

Review 1.  Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia.

Authors:  Maria Hernandez-Valladares; Elise Aasebø; Frode Selheim; Frode S Berven; Øystein Bruserud
Journal:  Proteomes       Date:  2016-08-22

Review 2.  The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.

Authors:  Ina Nepstad; Kimberley Joanne Hatfield; Ida Sofie Grønningsæter; Håkon Reikvam
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

Review 3.  Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients.

Authors:  Elise Aasebø; Rakel B Forthun; Frode Berven; Frode Selheim; Maria Hernandez-Valladares
Journal:  Curr Pharm Biotechnol       Date:  2016       Impact factor: 2.837

Review 4.  The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives.

Authors:  Maria Hernandez-Valladares; Øystein Bruserud; Frode Selheim
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.